Skip to main content
Erschienen in: Current Gastroenterology Reports 3/2017

01.03.2017 | Large Intestine (B Cash, Section Editor)

Opioid-Related Constipation in Patients With Non-cancer Pain Syndromes: a Review of Evidence-Based Therapies and Justification for a Change in Nomenclature

verfasst von: Darren M. Brenner, Emily Stern, Brooks D. Cash

Erschienen in: Current Gastroenterology Reports | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Opioids are a mainstay in the treatment of chronic non-cancer pain syndromes, but their analgesic benefits come at a cost as opioid-related constipation occurs in 40–80% of individuals taking chronic opioids. Furthermore, as 10–20% of the population suffers from constipation at baseline, it should be expected that while a proportion of individuals will develop constipation as a direct consequence of opioids (OIC), others will experience it as an exacerbation of their baseline constipation (OEC). Herein, we review the evidence-based data for treatments directed at opioid-related constipation focusing on individuals with non-cancer pain syndromes and provide a template for the development of differentiated treatment algorithms for OIC and OEC.

Recent Findings

Historical and current treatment protocols recommend traditional laxatives, but these are ineffective in up to 50%, due in part to the heterogeneous pathogenesis of constipation. Therapeutic decisions must be tailored to account for this overlapping pathogenesis.

Summary

OIC and OEC are distinct entities. As such, additional research and guidelines should address these as different patient populations.
Literatur
1.
Zurück zum Zitat CDC. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR. 2011;60:1487–92. CDC. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR. 2011;60:1487–92.
3.
Zurück zum Zitat •• Camilleri M, Drossman DA, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. J Neurogastroenterol Motil. 2014;26(10):1386–95. First article to propose a multispecialty definition for OIC CrossRef •• Camilleri M, Drossman DA, Becker G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. J Neurogastroenterol Motil. 2014;26(10):1386–95. First article to propose a multispecialty definition for OIC CrossRef
4.
Zurück zum Zitat •• Lacy BE, Mearin D, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–407. Rome IV definition for OIC CrossRef •• Lacy BE, Mearin D, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–407. Rome IV definition for OIC CrossRef
5.
Zurück zum Zitat Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2-guidance. Pain Physician. 2012;15:S67–S116.PubMed Manchikanti L, Abdi S, Atluri S, et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2-guidance. Pain Physician. 2012;15:S67–S116.PubMed
6.
Zurück zum Zitat •• Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16:2324–37. Newest multispeciality consesus recommendations for treating OIC CrossRefPubMedPubMedCentral •• Argoff CE, Brennan MJ, Camilleri M, et al. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16:2324–37. Newest multispeciality consesus recommendations for treating OIC CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat • Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with non-cancer pain. N Engl J Med. 2014;370:2387–96. Two phase III studies leading to approval of naloxegol for treatment of OIC in non-cancer pain patients CrossRefPubMed • Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with non-cancer pain. N Engl J Med. 2014;370:2387–96. Two phase III studies leading to approval of naloxegol for treatment of OIC in non-cancer pain patients CrossRefPubMed
10.
Zurück zum Zitat Webster L, Chey WD, Tack J, et al. Randomized clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771–9.CrossRefPubMed Webster L, Chey WD, Tack J, et al. Randomized clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther. 2014;40(7):771–9.CrossRefPubMed
11.
Zurück zum Zitat Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12:554–62.CrossRefPubMed Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12:554–62.CrossRefPubMed
12.
Zurück zum Zitat Iyer SS, Randazzo BP, Tzanis EL, et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health. 2011;14:177–83.CrossRefPubMed Iyer SS, Randazzo BP, Tzanis EL, et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health. 2011;14:177–83.CrossRefPubMed
13.
Zurück zum Zitat Rauck RL, Peppin JF, Israel RJ, et al. Oral methylnaltrexone for the treatment of opioid-induced constipation in patients with noncancer pain. Gastroenterol. 2012;142(suppl 1):S160.CrossRef Rauck RL, Peppin JF, Israel RJ, et al. Oral methylnaltrexone for the treatment of opioid-induced constipation in patients with noncancer pain. Gastroenterol. 2012;142(suppl 1):S160.CrossRef
14.
Zurück zum Zitat Hale ME, Wild J, Reddy J, et al. Efficacy and safety of naldemedine for the treatment of opioid-induced constipation in subjects with chronic non-cancer pain receiving opioid therapy: results from two phase 3 clinical trials. Gastroenterology. 2016;150((4) suppl 1):A598. Hale ME, Wild J, Reddy J, et al. Efficacy and safety of naldemedine for the treatment of opioid-induced constipation in subjects with chronic non-cancer pain receiving opioid therapy: results from two phase 3 clinical trials. Gastroenterology. 2016;150((4) suppl 1):A598.
15.
Zurück zum Zitat Webster L, Nalamachu S, Yamada T, et al. Long-term safety and efficacy of naldemedine for the treatment of opioid-induced constipation in subjects with chronic non-cancer pain receiving opioid therapy: results from a 52-week phase 3 clinical trial. Postgrad Med. 2016;128(suppl2):5. Webster L, Nalamachu S, Yamada T, et al. Long-term safety and efficacy of naldemedine for the treatment of opioid-induced constipation in subjects with chronic non-cancer pain receiving opioid therapy: results from a 52-week phase 3 clinical trial. Postgrad Med. 2016;128(suppl2):5.
17.
Zurück zum Zitat Webster L, Brenner DM, Rolleri R, et al. All-cause mortality in placebo-controlled clinical trials of methylnaltrexone: a pooled analysis. Am J Gastroenterol. 2013;108(S1):1886. Webster L, Brenner DM, Rolleri R, et al. All-cause mortality in placebo-controlled clinical trials of methylnaltrexone: a pooled analysis. Am J Gastroenterol. 2013;108(S1):1886.
18.
Zurück zum Zitat Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29:329–41.CrossRefPubMed Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009;29:329–41.CrossRefPubMed
19.
Zurück zum Zitat Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci. 2011;56:1619–25.CrossRefPubMed Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci. 2011;56:1619–25.CrossRefPubMed
21.
Zurück zum Zitat Ueno R, Osama H, Habe T. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology. 2004;126:Abstract M 1109. Ueno R, Osama H, Habe T. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterology. 2004;126:Abstract M 1109.
22.
Zurück zum Zitat Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942–7.CrossRefPubMed Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2006;290:G942–7.CrossRefPubMed
23.
Zurück zum Zitat Mazen Jamal M, Adams AB, Jansen JP, et al. A randomized-placebo controlled trial of lubiprostone for opioid-induced constipation in chronic non-cancer pain. Am J Gastroenterol. 2015;110:725–32.CrossRefPubMedPubMedCentral Mazen Jamal M, Adams AB, Jansen JP, et al. A randomized-placebo controlled trial of lubiprostone for opioid-induced constipation in chronic non-cancer pain. Am J Gastroenterol. 2015;110:725–32.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat • Cryer BL, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioid induced constipation in patients with chronic, non-cancer pain. Pain Med. 2014;15:1825–34. Phase III study proving efficacy of lubiprostone for treating OIC in individuals consuming non-diphenylheptane opioids for non-malignanct pain syndromes CrossRefPubMedPubMedCentral • Cryer BL, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioid induced constipation in patients with chronic, non-cancer pain. Pain Med. 2014;15:1825–34. Phase III study proving efficacy of lubiprostone for treating OIC in individuals consuming non-diphenylheptane opioids for non-malignanct pain syndromes CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Cuppoletti J, Chakrabarti J, Tewari K, et al. Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents. Cell Biochem Biophys. 2013;66(1):53–63.CrossRefPubMed Cuppoletti J, Chakrabarti J, Tewari K, et al. Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents. Cell Biochem Biophys. 2013;66(1):53–63.CrossRefPubMed
26.
Zurück zum Zitat Spierings EH, Drossman DA, Cryer B, et al. A pooled analysis of response to lubiprostone in patients with opioid-induced constipation receiving non-methadone opioids versus methadone. Gastroenterol. 2014;146(5):2036.CrossRef Spierings EH, Drossman DA, Cryer B, et al. A pooled analysis of response to lubiprostone in patients with opioid-induced constipation receiving non-methadone opioids versus methadone. Gastroenterol. 2014;146(5):2036.CrossRef
27.
Zurück zum Zitat Amitiza (lubiprostone) capsules [package insert]. Deerfield: Takeda Pharmaceuticals America Inc; 2013. Amitiza (lubiprostone) capsules [package insert]. Deerfield: Takeda Pharmaceuticals America Inc; 2013.
30.
Zurück zum Zitat •• Brenner DM, Chey WD. An evidence-based review of novel and emerging therapies for constipation in patients taking opioid analgesics. Am J Gastroenterol Suppl. 2014;2:38–46. First recommendation to differentiate opioid-induced and associated constipation recognizing the role of other forms of constipation in the development of symptoms in individuals consuming opioids CrossRef •• Brenner DM, Chey WD. An evidence-based review of novel and emerging therapies for constipation in patients taking opioid analgesics. Am J Gastroenterol Suppl. 2014;2:38–46. First recommendation to differentiate opioid-induced and associated constipation recognizing the role of other forms of constipation in the development of symptoms in individuals consuming opioids CrossRef
Metadaten
Titel
Opioid-Related Constipation in Patients With Non-cancer Pain Syndromes: a Review of Evidence-Based Therapies and Justification for a Change in Nomenclature
verfasst von
Darren M. Brenner
Emily Stern
Brooks D. Cash
Publikationsdatum
01.03.2017
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 3/2017
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-017-0560-2

Weitere Artikel der Ausgabe 3/2017

Current Gastroenterology Reports 3/2017 Zur Ausgabe

Esophagus (J Clarke and N Ahuja, Section Editors)

Diagnosis of Swallowing Disorders: How We Interpret Pharyngeal Manometry

Esophagus (J Clarke and N Ahuja, Section Editors)

Recent Advances in Non-invasive Esophageal Tissue Sampling

Pediatric Gastroenterology (S Orenstein, Section Editor)

Donor Considerations in Fecal Microbiota Transplantation

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.